More on CCCC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.78 |
|
|||
| Open | $2.78 | ||||
| 52 Wk High | $0.30 | ||||
| 52 Wk Low | $0.30 | ||||
| Day High | $2.81 | ||||
| Day Low | $2.70 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,359,351 | ||||
- JPMorgan Starts C4 Therapeutics (CCCC) at Overweight
- Form 4 C4 Therapeutics, Inc. For: Oct 01 Filed by: Anderson Kenneth Carl
- Form 4 C4 Therapeutics, Inc. For: Oct 01 Filed by: GROGAN DONNA ROY
- Form 8-K C4 Therapeutics, Inc. For: Sep 25
- C4 Therapeutics shares cemsidomide biomarker data at myeloma meeting
- C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd I
- Form 4 C4 Therapeutics, Inc. For: Sep 18 Filed by: Adams Kendra
- C4 Therapeutics to present cemsidomide biomarker data at myeloma meeting
- C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd I
- Form 144 C4 Therapeutics, Inc. Filed by: Mossler Mark
Entities mentioned with CCCC
- FDA | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- Jefferies & Co | View Related Stories »
- IPO | View Related Stories »
- UBS | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
